Quick Takeaways
- Ikarian Capital, LLC filed SCHEDULE 13G/A for Avalo Therapeutics, Inc. Common Stock, $0.001 Par Value (AVTX).
- Disclosed ownership: 3.8%.
- Date of event: 30 Sep 2025.
Ikarian Capital, LLC - 30 Sep 2025 SCHEDULE 13G/A Report for Avalo Therapeutics, Inc. Common Stock, $0.001 Par Value (AVTX)
- Filing Manager
- Ikarian Capital, LLC
- Reporting Manager
- Ikarian Capital, LLC
- Symbol
- AVTX
- Shares outstanding
- 18,735,974 shares
- Disclosed Ownership
- 711,967 shares
- Ownership
- 3.8%
- Form type
- SCHEDULE 13G/A
- Filing time
- 14 Nov 2025, 18:26:50 UTC
- Date of event
- 30 Sep 2025
- Previous filing
- 15 May 2025
- SEC
- View on sec.gov
Quoteable Key Fact
"Ikarian Capital, LLC disclosed 3.8% ownership in Avalo Therapeutics, Inc. Common Stock, $0.001 Par Value (AVTX) on 30 Sep 2025."
What Changed
- Previous schedule filing date: 15 May 2025.
- Current filing was accepted on 14 Nov 2025, 18:26.
Why This Matters
- This page explains what this Schedule 13D/13G filing tells you before manager-level rows.
- You can verify ownership claims directly against the original SEC filing.
Official SEC Source
Backed by Schedule 13D/13G
Beneficial ownership values are sourced from the original SEC Schedule 13D/13G filing.
See Original FilingReporting Managers (2)
| Name | Ownership | Shares Owned | sole voting power | shared voting power | Signature | Title | CIK |
|---|---|---|---|---|---|---|---|
| Ikarian Capital, LLC | 3.8% | 711,967 | 0 | 711,967 | /s/ Neil Shahrestani | Neil Shahrestani, Sole Manager | |
| Neil Shahrestani | 3.8% | 711,967 | 0 | 711,967 | /s/ Neil Shahrestani | Neil Shahrestani |